Premium
Theravance Biopharma Inc (TBPH)
NASDAQ
Hot Features
Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
| Date | Nom du détenteur | Actions transigées | Fourchette de valeur ($) | Type d'opération | Fourchette de prix ($) | Actions en fin de déclaration | % de variation |
|---|---|---|---|---|---|---|---|
| 2026-06-29 | Madison Avenue Partners, LPSociété | -336,70k | 5,79M | Vente | 17,00 - 17,23 | 9,17M | -3,54% |
| 2026-06-15 | Ms. Rhonda F. FarnumChief Business Officer and Senior VP of Commercial & Medical Affairs | -13,31k | 218,17k | Automatic Disposition | 16,38 - 16,39 | 232,46k | -5,42% |
| 2026-05-20 | Mr. Rick E. WinninghamCEO & Director | -20,04k | 331,63k | Sale to Issuer | 16,55 | 1,75M | -1,13% |
| 2026-05-20 | Mr. Aziz SawafSenior VP of Operations Strategy & CFO | -8,67k | 143,49k | Sale to Issuer | 16,55 | 344,95k | -2,45% |
| 2026-05-20 | Dr. Aine MillerSenior VP of Development & Head of Ireland Office | -6,83k | 112,99k | Sale to Issuer | 16,55 | 177,33k | -3,71% |
| 2026-05-20 | Mr. Brett A. GrimaudSenior VP, General Counsel & Secretary | -8,83k | 146,12k | Sale to Issuer | 16,55 | 363,12k | -2,37% |
| 2026-05-20 | Ms. Rhonda F. FarnumChief Business Officer and Senior VP of Commercial & Medical Affairs | -5,68k | 93,97k | Sale to Issuer | 16,55 | 245,77k | -2,26% |
| 2026-03-16 | Ms. Rhonda F. FarnumChief Business Officer and Senior VP of Commercial & Medical Affairs | -31,07k | 433,64k | Automatic Disposition | 13,92 - 14,00 | 232,70k | -11,78% |
| 2026-02-20 | Mr. Rick E. WinninghamCEO & Director | -74,98k | 1,47M | Sale to Issuer | 19,66 | 1,69M | -4,24% |
| 2026-02-20 | Mr. Aziz SawafSenior VP of Operations Strategy & CFO | -20,67k | 406,41k | Sale to Issuer | 19,66 | 316,12k | -6,14% |
| 2026-02-20 | Dr. Aine MillerSenior VP of Development & Head of Ireland Office | -16,85k | 331,29k | Sale to Issuer | 19,66 | 184,16k | -8,38% |
| 2026-02-20 | Mr. Brett A. GrimaudSenior VP, General Counsel & Secretary | -20,83k | 409,58k | Sale to Issuer | 19,66 | 334,45k | -5,86% |
| 2026-02-20 | Ms. Rhonda F. FarnumChief Business Officer and Senior VP of Commercial & Medical Affairs | -13,93k | 273,84k | Sale to Issuer | 19,66 | 263,77k | -5,02% |
| 2025-12-03 | Ms. Rhonda F. FarnumChief Business Officer and Senior VP of Commercial & Medical Affairs | -31,07k | 582,50k | Automatic Disposition | 18,75 | 277,70k | -10,06% |
| 2025-11-26 | Mr. Eran BroshyInitié | -29,50k | 590,02k | Automatic Disposition | 20,00 | 34,05k | -46,42% |
| 2025-11-20 | Mr. Aziz SawafSenior VP of Operations Strategy & CFO | -18,63k | 333,42k | Sale to Issuer | 17,90 | 336,80k | -5,24% |
| 2025-11-20 | Dr. Aine MillerSenior VP of Development & Head of Ireland Office | -6,99k | 125,10k | Sale to Issuer | 17,90 | 201,01k | -3,36% |
| 2025-11-20 | Mr. Brett A. GrimaudSenior VP, General Counsel & Secretary | -19,02k | 340,53k | Sale to Issuer | 17,90 | 355,28k | -5,08% |
| 2025-11-20 | Ms. Rhonda F. FarnumChief Business Officer and Senior VP of Commercial & Medical Affairs | -9,06k | 162,17k | Sale to Issuer | 17,90 | 308,76k | -2,85% |
| 2025-11-20 | Mr. Rick E. WinninghamCEO & Director | -56,82k | 1,02M | Sale to Issuer | 17,90 | 1,77M | -3,12% |
| 2025-11-19 | Mr. Rick E. WinninghamCEO & Director | -9,90k | 0,00 | Other Disposition | - | 1,77M | -0,56% |
| 2025-11-11 | Mr. Eran BroshyInitié | -45,00k | 809,25k | Automatic Disposition | 17,00 - 18,50 | 49,56k | -47,59% |
| 2025-08-20 | Mr. Rick E. WinninghamCEO & Director | -15,39k | 206,13k | Sale to Issuer | 13,39 | 1,82M | -0,84% |
| 2025-08-20 | Mr. Aziz SawafSenior VP of Operations Strategy & CFO | -9,37k | 125,44k | Sale to Issuer | 13,39 | 355,42k | -2,57% |
| 2025-08-20 | Dr. Aine MillerSenior VP of Development & Head of Ireland Office | -6,99k | 93,58k | Sale to Issuer | 13,39 | 208,00k | -3,25% |
| 2025-08-20 | Mr. Brett A. GrimaudSenior VP, General Counsel & Secretary | -9,76k | 130,71k | Sale to Issuer | 13,39 | 374,31k | -2,54% |
| 2025-08-20 | Ms. Rhonda F. FarnumChief Business Officer and Senior VP of Commercial & Medical Affairs | -9,10k | 121,80k | Sale to Issuer | 13,39 | 317,82k | -2,78% |
| 2025-07-14 | Ms. Rhonda F. FarnumChief Business Officer and Senior VP of Commercial & Medical Affairs | -10,00k | 113,87k | Automatic Disposition | 11,39 | 326,92k | -2,97% |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
S'inscrire avec l'e-mail
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.
